Abstract: Described herein are gene signatures providing prognostic, diagnostic, treatment and molecular subtype classifications of cancers through genomic and epigenomic profiling, including immune checkpoint regulators such as programmed death ligand 1 (PDL-1). Using methods and compositions described herein, specific and sensitive detection of biomarkers of interest is provided. Such biomarkers are indicative of disease pathogenesis, which provides opportunity for selection of treatment, including treatment regimes directed at overcoming resistance mechanisms.

Abstract: Provided herein are methods for differentiating tumor and non-tumor (e.g., clonal hematopoiesis of indeterminate potential (CHIP)) origin nucleic acid variants from one another in a test sample obtained from a test subject at least partially using a computer. Other aspects are directed to methods of treating disease in subjects. Yet other aspects include related systems and computer readable media used to differentiating tumor and non-tumor origin nucleic acid variants from one another.

Abstract: Provided herein are compositions comprising partially hydrogenated farnesene. In certain embodiments, the compositions are useful as solvents, degreasers, cleaning products, personal care products, and for other uses. Also provided herein are methods of making the compositions and methods of their use.

Abstract: Provided herein are compositions comprising partially hydrogenated farnesene. In certain embodiments, the compositions are useful as solvents, degreasers, cleaning products, personal care products, and for other uses. Also provided herein are methods of making the compositions and methods of their use.